The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice.
Thyroid hormone receptor (TR) agonists have been proposed as therapeutic agents to treat non-alcoholic fatty liver disease (NAFLD) and insulin resistance. We investigated the ability of the TR agonists GC-1 and KB2115 to reduce hepatic steatosis in ob/ob mice. Both compounds markedly reduced hepatic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4388544?pdf=render |
| _version_ | 1818571526621888512 |
|---|---|
| author | Alexandro J Martagón Jean Z Lin Stephanie L Cimini Paul Webb Kevin J Phillips |
| author_facet | Alexandro J Martagón Jean Z Lin Stephanie L Cimini Paul Webb Kevin J Phillips |
| author_sort | Alexandro J Martagón |
| collection | DOAJ |
| description | Thyroid hormone receptor (TR) agonists have been proposed as therapeutic agents to treat non-alcoholic fatty liver disease (NAFLD) and insulin resistance. We investigated the ability of the TR agonists GC-1 and KB2115 to reduce hepatic steatosis in ob/ob mice. Both compounds markedly reduced hepatic triglyceride levels and ameliorated hepatic steatosis. However, the amelioration of fatty liver was not sufficient to improve insulin sensitivity in these mice and reductions in hepatic triglycerides did not correlate with improvements in insulin sensitivity or glycemic control. Instead, the effects of TR activation on glycemia varied widely and were found to depend upon the time of treatment as well as the compound and dosage used. Lower doses of GC-1 were found to further impair glycemic control, while a higher dose of the same compound resulted in substantially improved glucose tolerance and insulin sensitivity, despite all doses being equally effective at reducing hepatic triglyceride levels. Improvements in glycemic control and insulin sensitivity were observed only in treatments that also increased body temperature, suggesting that the induction of thermogenesis may play a role in mediating these beneficial effects. These data illustrate that the relationship between TR activation and insulin sensitivity is complex and suggests that although TR agonists may have value in treating NAFLD, their effect on insulin sensitivity must also be considered. |
| first_indexed | 2024-12-14T13:57:01Z |
| format | Article |
| id | doaj.art-f5ed8dc9a2184582a876d142fea86c63 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T13:57:01Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f5ed8dc9a2184582a876d142fea86c632022-12-21T22:58:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012298710.1371/journal.pone.0122987The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice.Alexandro J MartagónJean Z LinStephanie L CiminiPaul WebbKevin J PhillipsThyroid hormone receptor (TR) agonists have been proposed as therapeutic agents to treat non-alcoholic fatty liver disease (NAFLD) and insulin resistance. We investigated the ability of the TR agonists GC-1 and KB2115 to reduce hepatic steatosis in ob/ob mice. Both compounds markedly reduced hepatic triglyceride levels and ameliorated hepatic steatosis. However, the amelioration of fatty liver was not sufficient to improve insulin sensitivity in these mice and reductions in hepatic triglycerides did not correlate with improvements in insulin sensitivity or glycemic control. Instead, the effects of TR activation on glycemia varied widely and were found to depend upon the time of treatment as well as the compound and dosage used. Lower doses of GC-1 were found to further impair glycemic control, while a higher dose of the same compound resulted in substantially improved glucose tolerance and insulin sensitivity, despite all doses being equally effective at reducing hepatic triglyceride levels. Improvements in glycemic control and insulin sensitivity were observed only in treatments that also increased body temperature, suggesting that the induction of thermogenesis may play a role in mediating these beneficial effects. These data illustrate that the relationship between TR activation and insulin sensitivity is complex and suggests that although TR agonists may have value in treating NAFLD, their effect on insulin sensitivity must also be considered.http://europepmc.org/articles/PMC4388544?pdf=render |
| spellingShingle | Alexandro J Martagón Jean Z Lin Stephanie L Cimini Paul Webb Kevin J Phillips The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. PLoS ONE |
| title | The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. |
| title_full | The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. |
| title_fullStr | The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. |
| title_full_unstemmed | The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. |
| title_short | The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. |
| title_sort | amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob ob mice |
| url | http://europepmc.org/articles/PMC4388544?pdf=render |
| work_keys_str_mv | AT alexandrojmartagon theameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT jeanzlin theameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT stephanielcimini theameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT paulwebb theameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT kevinjphillips theameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT alexandrojmartagon ameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT jeanzlin ameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT stephanielcimini ameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT paulwebb ameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice AT kevinjphillips ameliorationofhepaticsteatosisbythyroidhormonereceptoragonistsisinsufficienttorestoreinsulinsensitivityinobobmice |